Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT DUAL PAK versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT DUAL PAK versus NYSTEX.
MONISTAT DUAL- PAK vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity. Tioconazole, also an imidazole, similarly inhibits ergosterol synthesis.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
Intravaginal: One applicatorful of 6.5% miconazole nitrate cream (1200 mg) at bedtime as a single dose. Topical: Apply 2% miconazole nitrate cream to affected area twice daily for 2 weeks.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
The terminal elimination half-life of miconazole following intravenous administration is approximately 24 hours (range 20-30 hours). This supports once-daily dosing for systemic infections, though topical application yields negligible systemic absorption.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Approximately 90% of an absorbed dose is eliminated in feces as unchanged drug and metabolites; less than 1% is excreted renally as unchanged drug. Biliary excretion is the primary route for the absorbed fraction.
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal